Tag Archives: Global IP

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, pricing, Strategy | Also tagged , , , , , , , | 6 Comments
  • Categories

  • Meta